Maxygen, (FRA:MYN) FCF Margin % : -56,050.00% (As of Mar. 2013)

View and export this data going back to . Start your Free Trial

What is Maxygen, FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Maxygen,'s Free Cash Flow for the three months ended in Mar. 2013 was €-1.12 Mil. Maxygen,'s Revenue for the three months ended in Mar. 2013 was €0.00 Mil. Therefore, Maxygen,'s FCF Margin % for the quarter that ended in Mar. 2013 was -56,050.00%.

As of today, Maxygen,'s current FCF Yield % is 0.00%.

The historical rank and industry rank for Maxygen,'s FCF Margin % or its related term are showing as below:

FRA:MYN' s FCF Margin % Range Over the Past 10 Years
Min: 0 Med: 0 Max: 86.93
Current: 86.93

During the past 13 years, the highest FCF Margin % of Maxygen, was 86.93%. The lowest was 0.00%. And the median was 0.00%.

FRA:MYN's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -147.18 vs FRA:MYN: 86.93

Maxygen, FCF Margin % Historical Data

The historical data trend for Maxygen,'s FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maxygen, FCF Margin % Chart

Maxygen, Annual Data

Trend

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

FCF Margin %

Get a 7-Day Free Trial

58.21

-56.16

-18.95

-1,066.67

82.77

Maxygen, Quarterly Data
	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13
FCF Margin %	Get a 7-Day Free Trial															-40,120.00	94.11	-30,300.00	-	-56,050.00

Competitive Comparison of Maxygen,'s FCF Margin %

For the Biotechnology subindustry, Maxygen,'s FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Maxygen,'s FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maxygen,'s FCF Margin % distribution charts can be found below:

* The bar in red indicates where Maxygen,'s FCF Margin % falls into.

Maxygen, FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Maxygen,'s FCF Margin for the fiscal year that ended in Dec. 2012 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2012 )	/	Revenue (A: Dec. 2012 )
	=	18.928	/	22.868
	=	82.77 %

Maxygen,'s FCF Margin for the quarter that ended in Mar. 2013 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2013 )	/	Revenue (Q: Mar. 2013 )
	=	-1.121	/	0.002
	=	-56,050.00 %

Maxygen, FCF Margin % Related Terms

Thank you for viewing the detailed overview of Maxygen,'s FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Maxygen, (FRA:MYN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maxygen, Inc. (FRA:MYN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Maxygen, Inc., is incorporated in Delaware. It is a biotechnology company. It discovers and develops improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions. The Company's MAXY-G34 product candidate has been designed to be an improved next-generation pegylated, G-CSF for the treatment of chemotherapy-induced neutropenia. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The Company completed a Phase IIa clinical trial for its MAXY-G34 product candidate for the treatment of chemotherapy-induced neutropenia in breast cancer patients in which MAXY-G34 was safe and effective in reducing chemotherapy-induced neutropenia with no serious adverse events, drug-related grade 3 or 4 adverse events or immunogenicity reported in any patient receiving MAXY-G34. Adverse events were consistent with known side effects of G-CSF molecules. The Company is subject to regulation by the FDA and comparable regulatory agencies in foreign countries with respect to any development and commercialization of its MAXY-G34 product candidate or any other products it may acquire in the future.